after enrollment you will be assigned randomly to receive either orelabrutinib or a matching placebo tablet.

baseline assessments include a physical examination, disability scoring (edss), blood tests, and an mri scan of the brain.

you will begin taking one 80 mg oral tablet each day.

the tablet is taken by mouth with water, preferably at the same time each day.

the medication will be continued for the duration of the study as directed by the trial team.

you will attend scheduled visits every few months to monitor safety and effectiveness.

at each visit blood samples will be collected, your disability level will be reassessed, and any side effects will be recorded.

you will undergo mri scans of the brain at intervals defined by the study protocol to evaluate new or enlarging t2 lesions.

the scans help determine the impact of the study medication on disease activity.

your edss score will be measured at each visit to detect any confirmed disability progression.

the primary outcome is the time until a confirmed progression lasting at least 24 weeks.

at the end of the trial you will have a comprehensive evaluation including a final mri scan, blood tests, and disability assessment.

the data collected will be used to compare the effects of orelabrutinib with the placebo.